Try
BIOCRYST PHARMACEUTICALS INC
BCRXUnited States
35 filed reports · 380 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
35 reports · Dec 2015 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 28 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 16 | 2,979 | Jun 2021 to Jun 2026 |
| Current · 8-KSEC EDGAR | 14 | 28 | Dec 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 2,506 | Dec 2021 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 467 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 285 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,025 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 310 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 178 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 185 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 426 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 24, 2025 | 2 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Jan 10, 2025 | 2 | Open |
Financial data
380 concepts · 5,513 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial357 concepts · 5,056 facts · Dec 2018 to Jul 2026
- Royalty financing obligations36 · Dec 2022 to Jun 2026
- Stockholders equity (US GAAP)35 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value33 · Dec 2019 to Jun 2026
- Net income loss33 · Dec 2019 to Jun 2026
- Stock issued during period value stock options exercised33 · Dec 2019 to Jun 2026
- Comprehensive income net of tax32 · Dec 2019 to Jun 2026
- Cost of goods and services sold (US GAAP)32 · Dec 2019 to Jun 2026
- Costs and expenses32 · Dec 2019 to Jun 2026
- Gain loss on foreign currency derivative instruments not designated as hedging instruments32 · Dec 2019 to Jun 2026
- Interest and other income32 · Dec 2019 to Jun 2026
- Operating income loss32 · Dec 2019 to Jun 2026
- Research and development expense32 · Dec 2019 to Jun 2026
- Revenue32 · Dec 2019 to Jun 2026
- Selling general and administrative expense32 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable31 · Dec 2019 to Jun 2026
- Increase decrease in inventories31 · Dec 2019 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets31 · Dec 2019 to Jun 2026
- Increase decrease in receivables31 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities31 · Dec 2019 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent31 · Jun 2020 to Jun 2026
- Payments to acquire available for sale securities debt31 · Dec 2019 to Jun 2026
- Payments to acquire productive assets31 · Dec 2019 to Jun 2026
Segment20 concepts · 279 facts · Dec 2022 to Jun 2026
- Research and development expense75 · Dec 2022 to Dec 2025
- Research and development expense excluding acquired in process cost32 · Mar 2025 to Jun 2026
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Interest expense nonoperating14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Foreign currency transaction gain loss before tax12 · Dec 2023 to Jun 2026
- Interest income operating12 · Dec 2023 to Jun 2026
- Selling general and administrative expense11 · Dec 2022 to Mar 2026
- Gains losses on extinguishment of debt10 · Dec 2023 to Jun 2026
- Other income (IFRS)9 · Dec 2023 to Mar 2026
- General and administrative expense (US GAAP)7 · Dec 2023 to Jun 2026
- Share based compensation7 · Dec 2023 to Jun 2026
- Interest and other income5 · Dec 2022 to Mar 2025
- Royalty5 · Dec 2022 to Mar 2025
- Selling and marketing expense (US GAAP)5 · Dec 2023 to Jun 2026
- Segment reporting other item amount3 · Dec 2022 to Dec 2024
- Other operating income expense net2 · Jun 2025 to Jun 2026
Product1 concepts · 150 facts · Dec 2019 to Jun 2026
- Revenue150 · Dec 2019 to Jun 2026
Guidance2 concepts · 28 facts · Feb 2016 to Aug 2026
- Free Cash Flow Guidance14 · Feb 2016 to Mar 2019
- Revenue Guidance14 · Aug 2022 to Aug 2026
Segments
429 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 279 facts
- Reportable279 · Dec 2022 to Jun 2026
Product or service10 members · 150 facts
- Product32 · Dec 2019 to Jun 2026
- Collaborative And Other Research And Development31 · Dec 2019 to Mar 2026
- ORLADEYO23 · Dec 2021 to Jun 2026
- Other Income From Contract With Customer22 · Dec 2021 to Mar 2026
- Royalty15 · Dec 2019 to Dec 2022
- Milestone9 · Jun 2020 to Dec 2022
- License And Other Revenues7 · Dec 2023 to Jun 2026
- License5 · Dec 2023 to Mar 2026
- Milestone Revenue4 · Jun 2021 to Sep 2022
- License Revenue And Other Income From Contract With Customer2 · Jun 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.